(Q50570346)

English

Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.

scientific article published on 6 January 2010

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

1 reference

based on heuristic

inferred from title

author name string

Christian Schindlbeck

1

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

D Mayr

2

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

C Olivier

3

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

B Rack

4

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

V Engelstaedter

5

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

J Jueckstock

6

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

C Jenderek

7

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

U Andergassen

8

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

U Jeschke

9

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

K Friese

10

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

publication date

6 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

136

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

7

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

1029-1037

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topoisomerase IIα gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anthracycline cardiotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Roles of DNA topoisomerases in chromosome segregation and mitosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast canc

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of screening and adjuvant therapy on mortality from breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systematic review of HER2 breast cancer testing

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2/neu and topoisomerase IIalpha in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cellular roles of dna topoisomerases: a molecular perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20052594

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-009-0748-4

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20052594

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50570346&oldid=2210367500"